Drug intelligence / Profile preview

TGI-14

Development stage: Preclinical
Lead developer: TG ImmunoPharma
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

TGI-14 is a preclinical tri-specific T-cell engager (TCE) being developed by TG ImmunoPharma for the treatment of cancer. Engineered using the company's proprietary pH-selective TCE platform, TGI-14 is designed to selectively activate within the acidic microenvironment of solid tumors. This localized activation allows the antibody to recruit and engage T cells via CD3 to eliminate tumor cells while significantly reducing systemic and peripheral toxicities, such as cytokine release syndrome, which are commonly associated with conventional T-cell engagers.

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on TGI-14.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TGI-14.